Welcome to our dedicated page for Cytek Biosciences SEC filings (Ticker: CTKB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytek Biosciences, Inc. (Nasdaq: CTKB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public issuer on the Nasdaq Global Select Market. These documents help investors and analysts understand Cytek’s financial condition, operating results and governance as a cell analysis solutions company focused on Full Spectrum Profiling™ (FSP®) flow cytometry instruments, reagents and services.
Cytek submits Form 10-Q quarterly reports and Form 10-K annual reports, which include details on revenue from products, services and reagents, gross margins, operating expenses such as research and development, sales and marketing, and general and administrative costs, as well as information on cash and marketable securities. These filings also discuss risk factors, market conditions and other elements relevant to its analytical laboratory instrument manufacturing business.
The company also files Form 8-K current reports to disclose material events. Recent 8-K filings have covered quarterly financial results under Item 2.02 (Results of Operations and Financial Condition) and outcomes of the annual meeting of stockholders under Item 5.07, including votes on director elections, executive compensation and ratification of the independent registered public accounting firm.
In addition, investors can review exhibits attached to these filings, such as press releases furnished as Exhibit 99.1, which provide narrative context for the numbers reported. Over time, the filings record Cytek’s progress in areas such as recurring revenue growth from services and reagents, expansion of its installed instrument base and capital allocation decisions.
On Stock Titan, Cytek’s SEC filings are updated in near real time from the EDGAR system. AI-powered summaries highlight key points from lengthy 10-K and 10-Q reports, and help users quickly identify information on revenue composition, operating trends and risk disclosures. The page also makes it easier to locate Form 4 and other insider-related filings when available, supporting research into trading activity and governance practices at CTKB.
Cytek Biosciences director and Chief Technology Officer Yan Ming reported multiple Form 4 transactions on 08/18/2025 related to the vesting of Restricted Stock Units (RSUs). The filings show vesting events that increased Mr. Yan's direct beneficial ownership to 6,058,887 shares of common stock after the reported transactions. Several tranches vested on 08/18/2025 totaling 20,?231 RSUs (1,981 + 7,363 + 5,525 + 6,162) and certain shares were withheld to satisfy tax withholding obligations at a price of $4.06 per share for the withheld amounts. The RSU awards follow multi‑year vesting schedules described in the explanation, with quarterly or annual vesting components.
Insider Form 4 for Cytek Biosciences, Inc. (CTKB) reports that Philippe Busque, SVP, Global Sales and Services and a director, had multiple restricted stock unit (RSU) vesting events on 08/18/2025 that increased his beneficial ownership. A series of RSU awards converted into common shares: 1,536; 2,210; and 3,625 RSUs became vested and reflected as acquired shares. The filing also shows withholding/surrender of shares to satisfy tax obligations related to the vesting, reducing net share additions.
Valerie Barnett, Chief Legal Officer of Cytek Biosciences (CTKB), reported multiple transactions on August 18, 2025 related to restricted stock units (RSUs) that vested. The filing shows vesting and issuance of RSUs in several tranches: 2,016; 3,681; 7,735; and 10,875 units. Shares were withheld to cover tax obligations: 786, 1,434, 3,000 and 3,609 shares respectively. After the reported transactions, Barnett beneficially owned 155,888 shares of common stock.
Insider transactions by Cytek Biosciences (CTKB): The company's President and CEO and a director, Jiang Wenbin, reported multiple transactions on 08/18/2025 relating to Restricted Stock Units (RSUs) that vested. Several RSU awards converted into shares: 6,758; 11,781; 22,100; and 29,002 RSUs were reported as vested and credited as common stock. To satisfy tax withholding on the vesting, the issuer withheld and surrendered shares in amounts of 1,646; 2,869; 5,382; and 7,062 at an indicated price of $4.06 per share. After these transactions, the filing shows beneficial ownership tallies following each line, with reported direct ownership figures such as 5,321,479 shares following the largest aggregation. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
William D. McCombe, Chief Financial Officer and Director of Cytek Biosciences, Inc. (CTKB), reported changes in beneficial ownership related to vesting of restricted stock units on 08/18/2025.
The filing shows two RSU vesting events recorded as acquisitions of 6,320 and 13,051 RSUs (each RSU convertible into one share). To satisfy tax withholding on the vesting, the issuer withheld 2,462 and 5,084 shares at a per-share price of $4.06. Post-transaction ownership figures reported in the form include multiple balances (for common stock and underlying derivative holdings), with derivative share totals of 6,320 and 13,051 underlying shares and aggregate beneficial ownership figures shown in the filing. The RSUs vest over four years on a specified schedule described in the explanations. The form was signed by an attorney-in-fact on 08/20/2025.
Cytek Biosciences director Michael Holder received a grant of 2,181 Restricted Stock Units (RSUs) reported on Form 4 with a transaction date of 08/18/2025. Each RSU converts to one share of common stock upon vesting; the filing shows these RSUs were reported as acquired at a $0 price and increased the reporting person’s beneficial ownership to 10,178 shares following the transaction. The RSU award vests per a schedule described in the filing, with portions vesting on specified dates (including August 18 and November 18 milestones) over multiple years until fully vested.
Richard Chin, a director of Cytek Biosciences, Inc. (CTKB), was awarded 4,071 restricted stock units (RSUs) that convert one-for-one into common shares. The RSUs were granted on 08/18/2025 and are reported as 4,071 shares beneficially owned following the award. The filing shows the award has a $0 exercise price because these are restricted stock units rather than paid stock options.
The RSUs vest on a staggered schedule: 2/36 of the total vests on 08/18/2025; 3/36 vests on 11/18/2025 and each November 18 thereafter; 3/36 vests on 03/10/2026 and each March 10 thereafter; 3/36 vests on 05/18/2026 and each May 18 thereafter; and 3/36 vests on 08/18/2026 and each August 18 thereafter until fully vested. The report was signed by an attorney-in-fact on 08/20/2025.
FAQ
What is the current stock price of Cytek Biosciences (CTKB)?
What is the market cap of Cytek Biosciences (CTKB)?
